{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:42:23Z","timestamp":1793367743556,"version":"4.5.0"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T00:00:00Z","timestamp":1751068800000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Pediatr"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Respiratory syncytial virus (RSV) is the most common cause of pediatric acute lower respiratory tract infection worldwide. In Singapore, RSV substantially contributes to the morbidity and mortality of children aged\u2009&lt;\u20095\u00a0years, particularly during their first year of life, with hospitalization rates peaking during epidemic outbreaks. This expert consensus paper aims to provide an overview of the RSV disease burden, unmet needs, and the urgency for RSV prevention in all infants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>A comprehensive literature review was conducted using Medline via PubMed, to identify relevant studies, including randomized controlled trials, observational studies, systematic reviews, and meta-analyses, related to RSV burden and prevention and nirsevimab. A multidisciplinary group of physicians with RSV expertise from leading institutions in Singapore reviewed the literature on RSV-related topics, convened to deliberate and formulate evidence-based recommendations, summarizing the overall disease burden, unmet needs, and the optimal implementation of an immunization strategy for all infant protection against RSV infections in Singapore. Premeeting and in-meeting surveys were conducted to guide the development of final consensus recommendations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Epidemiology and burden of RSV in Singapore, current protection against RSV infections in infants, implementations of nirsevimab, and optimization of nirsevimab implementation in Singapore were discussed in this study. Although RSV brings substantial burden with underestimated costs, palivizumab is the only approved product for RSV prevention in Singapore. Existing evidences reveal that nirsevimab has a good safety profile and is effective in preventing RSV lower respiratory tract infections. Seven statements were formulated on the epidemiology and burden of RSV in Singapore, with emphasis on its high incidence and associated healthcare cost, and the clinical efficacy and safety of nirsevimab as a basis of its implementation for all infant protection in Singapore.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The burden of RSV disease in young children is substantial, especially in those\u2009&lt;\u20092\u00a0years old, accounting for up to 47% of bronchiolitis and pneumonia admissions in children\u2009&lt;\u20096\u00a0months. The administration of a single dose of nirsevimab may be offered to infants at birth for the prevention of RSV in Singapore.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s12519-025-00926-2","type":"journal-article","created":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T00:21:15Z","timestamp":1751070075000},"page":"552-565","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Expert consensus on the burden of respiratory syncytial virus disease and the utility of nirsevimab for disease prevention and protection of infants"],"prefix":"10.1007","volume":"21","author":[{"given":"Daniel Y. T.","family":"Goh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching Kit","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si Min","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poh Choo","family":"Khoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koh Cheng","family":"Thoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bee Wah","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chee Fu","family":"Yung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,28]]},"reference":[{"key":"926_CR1","doi-asserted-by":"publisher","first-page":"880368","DOI":"10.3389\/fimmu.2022.880368","volume":"13","author":"S Esposito","year":"2022","unstructured":"Esposito S, Abu Raya B, Baraldi E, Flanagan K, Martinon Torres F, Tsolia M, et al. RSV prevention in all infants: which is the most preferable strategy? Front Immunol. 2022;13:880368.","journal-title":"Front Immunol"},{"key":"926_CR2","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/s41541-023-00734-7","volume":"8","author":"TJ Ruckwardt","year":"2023","unstructured":"Ruckwardt TJ. The road to approved vaccines for respiratory syncytial virus. NPJ Vaccines. 2023;8:138.","journal-title":"NPJ Vaccines"},{"key":"926_CR3","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1542\/pir.35.12.519","volume":"35","author":"G Piedimonte","year":"2014","unstructured":"Piedimonte G, Perez MK. Respiratory syncytial virus infection and bronchiolitis. Pediatr Rev. 2014;35:519\u201330.","journal-title":"Pediatr Rev"},{"key":"926_CR4","doi-asserted-by":"publisher","first-page":"708939","DOI":"10.3389\/fimmu.2021.708939","volume":"12","author":"S Esposito","year":"2021","unstructured":"Esposito S, Abu-Raya B, Bonanni P, Cahn-Sellem F, Flanagan KL, Martinon Torres F, et al. Coadministration of anti-viral monoclonal antibodies with routine pediatric vaccines and implications for nirsevimab use: a white paper. Front Immunol. 2021;12:708939.","journal-title":"Front Immunol"},{"key":"926_CR5","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","volume":"399","author":"Y Li","year":"2022","unstructured":"Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, Gill CJ, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399:2047\u201364.","journal-title":"Lancet"},{"key":"926_CR6","first-page":"39","volume":"372","author":"CB Hall","year":"2013","unstructured":"Hall CB, Sim\u0151es EA, Anderson LJ. Clinical and epidemiologic features of respiratory syncytial virus. Curr Top Microbiol Immunol. 2013;372:39\u201357.","journal-title":"Curr Top Microbiol Immunol"},{"key":"926_CR7","doi-asserted-by":"publisher","first-page":"209","DOI":"10.37201\/req\/006.2024","volume":"37","author":"I Sanz-Mu\u00f1oz","year":"2024","unstructured":"Sanz-Mu\u00f1oz I, S\u00e1nchez-de Prada L, Castrodeza-Sanz J, Eiros JM. Microbiological and epidemiological features of respiratory syncytial virus. Rev Esp Quimioter. 2024;37:209\u201320.","journal-title":"Rev Esp Quimioter"},{"key":"926_CR8","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.3390\/vaccines11121809","volume":"11","author":"KC See","year":"2023","unstructured":"See KC. Vaccination for respiratory syncytial virus: a narrative review and primer for clinicians. Vaccines. 2023;11:1809.","journal-title":"Vaccines"},{"key":"926_CR9","doi-asserted-by":"publisher","first-page":"222","DOI":"10.5005\/jp-journals-11002-0073","volume":"2","author":"A Maheshwari","year":"2023","unstructured":"Maheshwari A, Singh S, Namazova I, Benjamin JT, Wang Y. Respiratory syncytial virus infections in neonates: a persisting problem. Newborn. 2023;2:222\u201334.","journal-title":"Newborn"},{"key":"926_CR10","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.3390\/vaccines11121797","volume":"11","author":"E Kopera","year":"2023","unstructured":"Kopera E, Czajka H, Zapolnik P, Mazur A. New insights on respiratory syncytial virus prevention. Vaccines. 2023;11:1797.","journal-title":"Vaccines"},{"key":"926_CR11","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1146\/annurev-immunol-051116-052206","volume":"35","author":"PJM Openshaw","year":"2017","unstructured":"Openshaw PJM, Chiu C, Culley FJ, Johansson C. Protective and harmful immunity to RSV infection. Annu Rev Immunol. 2017;35:501\u201332.","journal-title":"Annu Rev Immunol"},{"key":"926_CR12","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1164\/ajrccm.161.5.9906076","volume":"161","author":"N Sigurs","year":"2000","unstructured":"Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med. 2000;161:1501\u20137.","journal-title":"Am J Respir Crit Care Med"},{"key":"926_CR13","doi-asserted-by":"publisher","first-page":"e87162","DOI":"10.1371\/journal.pone.0087162","volume":"9","author":"K Zomer-Kooijker","year":"2014","unstructured":"Zomer-Kooijker K, van der Ent CK, Ermers MJ, Uiterwaal CS, Rovers MM, Bont LJ, et al. Increased risk of wheeze and decreased lung function after respiratory syncytial virus infection. PLoS ONE. 2014;9:e87162.","journal-title":"PLoS ONE"},{"key":"926_CR14","doi-asserted-by":"publisher","first-page":"S628","DOI":"10.1093\/infdis\/jiz311","volume":"222","author":"T Shi","year":"2020","unstructured":"Shi T, Ooi Y, Zaw EM, Utjesanovic N, Campbell H, Cunningham S, et al. Association between respiratory syncytial virus-associated acute lower respiratory infection in early life and recurrent wheeze and asthma in later childhood. J Infect Dis. 2020;222:S628\u201333.","journal-title":"J Infect Dis"},{"key":"926_CR15","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1007\/s12519-023-00743-5","volume":"19","author":"MY Jiang","year":"2023","unstructured":"Jiang MY, Duan YP, Tong XL, Huang QR, Jia MM, Yang WZ, et al. Clinical manifestations of respiratory syncytial virus infection and the risk of wheezing and recurrent wheezing illness: a systematic review and meta-analysis. World J Pediatr. 2023;19:1030\u201340.","journal-title":"World J Pediatr"},{"key":"926_CR16","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1002\/ppul.24676","volume":"55","author":"J Coutts","year":"2020","unstructured":"Coutts J, Fullarton J, Morris C, Grubb E, Buchan S, Rodgers-Gray B, et al. Association between respiratory syncytial virus hospitalization in infancy and childhood asthma. Pediatr Pulmonol. 2020;55:1104\u201310.","journal-title":"Pediatr Pulmonol"},{"key":"926_CR17","doi-asserted-by":"publisher","first-page":"S680","DOI":"10.1093\/infdis\/jiz683","volume":"222","author":"S Zhang","year":"2020","unstructured":"Zhang S, Akmar LZ, Bailey F, Rath BA, Alchikh M, Schweiger B, et al. Cost of respiratory syncytial virus-associated acute lower respiratory infection management in young children at the regional and global level: a systematic review and meta-analysis. J Infect Dis. 2020;222:S680\u20137.","journal-title":"J Infect Dis"},{"key":"926_CR18","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/irv.12884","volume":"15","author":"Y Li","year":"2021","unstructured":"Li Y, Wang X, Msosa T, de Wit F, Murdock J, Nair H. The impact of the 2009 influenza pandemic on the seasonality of human respiratory syncytial virus: a systematic analysis. Influenza Other Respir Viruses. 2021;15:804\u201312.","journal-title":"Influenza Other Respir Viruses"},{"key":"926_CR19","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1093\/infdis\/jiy056","volume":"217","author":"P Obando-Pacheco","year":"2018","unstructured":"Obando-Pacheco P, Justicia-Grande AJ, Rivero-Calle I, Rodr\u00edguez-Tenreiro C, Sly P, Ramilo O, et al. Respiratory syncytial virus seasonality: a global overview. J Infect Dis. 2018;217:1356\u201364.","journal-title":"J Infect Dis"},{"key":"926_CR20","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/irv.12885","volume":"15","author":"L Staadegaard","year":"2021","unstructured":"Staadegaard L, Caini S, Wangchuk S, Thapa B, de Almeida WAF, de Carvalho FC, et al. Defining the seasonality of respiratory syncytial virus around the world: national and subnational surveillance data from 12 countries. Influenza Other Respir Viruses. 2021;15:732\u201341.","journal-title":"Influenza Other Respir Viruses"},{"key":"926_CR21","doi-asserted-by":"publisher","first-page":"e01828","DOI":"10.1128\/JCM.01828-20","volume":"59","author":"DE Tabor","year":"2020","unstructured":"Tabor DE, Fernandes F, Langedijk AC, Wilkins D, Lebbink RJ, Tovchigrechko A, et al. Global molecular epidemiology of respiratory syncytial virus from the 2017\u20132018 INFORM-RSV study. J Clin Microbiol. 2020;59:e01828\u201320.","journal-title":"J Clin Microbiol"},{"key":"926_CR22","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.3201\/eid2506.180532","volume":"25","author":"J Yu","year":"2019","unstructured":"Yu J, Liu C, Xiao Y, Xiang Z, Zhou H, Chen L, et al. Respiratory syncytial virus seasonality, Beijing, China, 2007\u20132015. Emerg Infect Dis. 2019;25:1127\u201335.","journal-title":"Emerg Infect Dis"},{"key":"926_CR23","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2147\/IDR.S396434","volume":"16","author":"YC Chuang","year":"2023","unstructured":"Chuang YC, Lin KP, Wang LA, Yeh TK, Liu PY. The impact of the COVID-19 pandemic on respiratory syncytial virus infection: a narrative review. Infect Drug Resist. 2023;16:661\u201375.","journal-title":"Infect Drug Resist"},{"key":"926_CR24","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3390\/v15020280","volume":"15","author":"G Pruccoli","year":"2023","unstructured":"Pruccoli G, Castagno E, Raffaldi I, Denina M, Barisone E, Baroero L, et al. The importance of RSV epidemiological surveillance: a multicenter observational study of RSV infection during the COVID-19 pandemic. Viruses. 2023;15:280.","journal-title":"Viruses"},{"key":"926_CR25","doi-asserted-by":"publisher","first-page":"1062726","DOI":"10.3389\/fpubh.2023.1062726","volume":"11","author":"T Miyama","year":"2023","unstructured":"Miyama T, Kakimoto K, Iritani N, Nishio T, Ukai T, Satsuki Y, et al. Exploring the threshold for the start of respiratory syncytial virus infection epidemic season using sentinel surveillance data in Japan. Front Public Health. 2023;11:1062726.","journal-title":"Front Public Health"},{"key":"926_CR26","doi-asserted-by":"publisher","first-page":"355","DOI":"10.15585\/mmwr.mm7214a1","volume":"72","author":"S Hamid","year":"2023","unstructured":"Hamid S, Winn A, Parikh R, Jones JM, McMorrow M, Prill MM, et al. Seasonality of respiratory syncytial virus - United States, 2017\u20132023. MMWR Morb Mortal Wkly Rep. 2023;72:355\u201361.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"926_CR27","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1186\/s12879-024-09509-4","volume":"24","author":"D Thindwa","year":"2024","unstructured":"Thindwa D, Li K, Cooper-Wootton D, Zheng Z, Pitzer VE, Weinberger DM. Global patterns of rebound to normal RSV dynamics following COVID-19 suppression. BMC Infect Dis. 2024;24:635.","journal-title":"BMC Infect Dis"},{"key":"926_CR28","doi-asserted-by":"publisher","first-page":"525","DOI":"10.21037\/tp-23-534","volume":"13","author":"N Homaira","year":"2024","unstructured":"Homaira N. Will nirsevimab be the holy grail for prevention of respiratory syncytial virus lower respiratory tract infections in infants? Transl Pediatr. 2024;13:525\u20139.","journal-title":"Transl Pediatr"},{"key":"926_CR29","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/0030-5073(73)90052-4","volume":"9","author":"DH Gustafson","year":"1973","unstructured":"Gustafson DH, Shukla RK, Delbecq A, Walster GW. A comparative study of differences in subjective likelihood estimates made by individuals, interacting groups, Delphi groups, and nominal groups. Organ Behav Hum Perform. 1973;9:280\u201391.","journal-title":"Organ Behav Hum Perform"},{"key":"926_CR30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jclinepi.2019.03.011","volume":"111","author":"D De Meyer","year":"2019","unstructured":"De Meyer D, Kottner J, Beele H, Schmitt J, Lange T, Van Hecke A, et al. Delphi procedure in core outcome set development: rating scale and consensus criteria determined outcome selection. J Clin Epidemiol. 2019;111:23\u201331.","journal-title":"J Clin Epidemiol"},{"key":"926_CR31","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.3201\/eid2607.190539","volume":"26","author":"CC Tam","year":"2020","unstructured":"Tam CC, Yeo KT, Tee N, Lin R, Mak TM, Thoon KC, et al. Burden and cost of hospitalization for respiratory syncytial virus in young children Singapore. Emerg Infect Dis. 2020;26:1489\u201396.","journal-title":"Emerg Infect Dis"},{"key":"926_CR32","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1111\/jpc.15267","volume":"57","author":"KWJ Tan","year":"2021","unstructured":"Tan KWJ, Yung CF, Maiwald M, Saffari SE, Thoon KC, Chong CY. Respiratory viral infections in hospitalised paediatric patients in the tropics. J Paediatr Child Health. 2021;57:559\u201365.","journal-title":"J Paediatr Child Health"},{"key":"926_CR33","doi-asserted-by":"publisher","first-page":"642","DOI":"10.11622\/smedj.2020075","volume":"62","author":"MW Lee","year":"2021","unstructured":"Lee MW, Goh AE. Mortality in children hospitalised with respiratory syncytial virus infection in Singapore. Singapore Med J. 2021;62:642\u20136.","journal-title":"Singapore Med J"},{"key":"926_CR34","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/irv.12730","volume":"14","author":"LW Ang","year":"2020","unstructured":"Ang LW, Mak TM, Cui L, Leo YS, Lee VJM, Lin RT. Characterisation of respiratory syncytial virus activity in children and adults presenting with acute respiratory illness at primary care clinics in Singapore, 2014\u20132018. Influenza Other Respir Viruses. 2020;14:412\u20139.","journal-title":"Influenza Other Respir Viruses"},{"key":"926_CR35","doi-asserted-by":"publisher","first-page":"20469","DOI":"10.1038\/s41598-020-76888-4","volume":"10","author":"ST Ali","year":"2020","unstructured":"Ali ST, Tam CC, Cowling BJ, Yeo KT, Yung CF. Meteorological drivers of respiratory syncytial virus infections in Singapore. Sci Rep. 2020;10:20469.","journal-title":"Sci Rep"},{"key":"926_CR36","doi-asserted-by":"publisher","first-page":"10931","DOI":"10.1038\/s41598-020-67969-5","volume":"10","author":"I Thongpan","year":"2020","unstructured":"Thongpan I, Vongpunsawad S, Poovorawan Y. Respiratory syncytial virus infection trend is associated with meteorological factors. Sci Rep. 2020;10:10931.","journal-title":"Sci Rep"},{"key":"926_CR37","doi-asserted-by":"publisher","first-page":"e0265288","DOI":"10.1371\/journal.pone.0265288","volume":"17","author":"YL Low","year":"2022","unstructured":"Low YL, Wong SY, Lee EKH, Muhammed MH. Prevalence of respiratory viruses among paediatric patients in acute respiratory illnesses in Malaysia. PLoS ONE. 2022;17:e0265288.","journal-title":"PLoS ONE"},{"key":"926_CR38","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1017\/S0950268899002824","volume":"123","author":"PK Chan","year":"1999","unstructured":"Chan PK, Sung RY, Fung KS, Hui M, Chik KW, Adeyemi-Doro FA, et al. Epidemiology of respiratory syncytial virus infection among paediatric patients in Hong Kong, China: seasonality and disease impact. Epidemiol Infect. 1999;123:257\u201362.","journal-title":"Epidemiol Infect"},{"key":"926_CR39","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.jfma.2021.08.012","volume":"121","author":"HC Lin","year":"2022","unstructured":"Lin HC, Liu YC, Hsing TY, Chen LL, Liu YC, Yen TY, et al. RSV pneumonia with or without bacterial co-infection among healthy children. J Formos Med Assoc. 2022;121:687\u201393.","journal-title":"J Formos Med Assoc"},{"key":"926_CR40","unstructured":"Acute respiratory infection surveillance reporting. 2025. https:\/\/www.health.qld.gov.au\/clinical-practice\/guidelines-procedures\/diseases-infection\/surveillance\/reports\/flu. Accessed 05 Mar 2025."},{"key":"926_CR41","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/1753-6405.12347","volume":"39","author":"S Paynter","year":"2015","unstructured":"Paynter S, Ware RS, Sly PD, Weinstein P, Williams G. Respiratory syncytial virus seasonality in tropical Australia. Aust N Z J Public Health. 2015;39:8\u201310.","journal-title":"Aust N Z J Public Health"},{"key":"926_CR42","doi-asserted-by":"publisher","first-page":"575","DOI":"10.47102\/annals-acadmedsg.2022168","volume":"51","author":"D Ravichandran","year":"2022","unstructured":"Ravichandran D, Lim JKB, Wee PH, Allen JC, Yung CF, Lee JH, et al. High burden of respiratory viral infection-associated mortality among critically ill children. Ann Acad Med Singap. 2022;51:575\u20137.","journal-title":"Ann Acad Med Singap"},{"key":"926_CR43","first-page":"100629","volume":"28","author":"A Shoukat","year":"2023","unstructured":"Shoukat A, Abdollahi E, Galvani AP, Halperin SA, Langley JM, Moghadas SM. Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of respiratory syncytial virus disease among infants in Canada: a simulation study. Lancet Reg Health Am. 2023;28:100629.","journal-title":"Lancet Reg Health Am"},{"key":"926_CR44","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13052-024-01617-w","volume":"50","author":"F Fortunato","year":"2024","unstructured":"Fortunato F, Campanozzi A, Maffei G, Arena F, Carri VD, Rollo T, et al. Respiratory syncytial virus-associated hospitalizations among children: an Italian retrospective observational study. Ital J Pediatr. 2024;50:45.","journal-title":"Ital J Pediatr"},{"key":"926_CR45","unstructured":"Palivizumab PI. 2014. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/103770s5185lbl.pdf. Accessed 01 Jul 2024."},{"key":"926_CR46","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1089\/ped.2024.0025","volume":"37","author":"H Balbi","year":"2024","unstructured":"Balbi H. Nirsevimab: a review. Pediatr Allergy Immunol Pulmonol. 2024;37:3\u20136.","journal-title":"Pediatr Allergy Immunol Pulmonol"},{"key":"926_CR47","doi-asserted-by":"publisher","first-page":"eaaj1928","DOI":"10.1126\/scitranslmed.aaj1928","volume":"9","author":"Q Zhu","year":"2017","unstructured":"Zhu Q, McLellan JS, Kallewaard NL, Ulbrandt ND, Palaszynski S, Zhang J, et al. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. Sci Transl Med. 2017;9:eaaj1928.","journal-title":"Sci Transl Med."},{"key":"926_CR48","doi-asserted-by":"publisher","first-page":"1283120","DOI":"10.3389\/fimmu.2023.1283120","volume":"14","author":"T Brady","year":"2023","unstructured":"Brady T, Cayatte C, Roe TL, Speer SD, Ji H, Machiesky L, et al. Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection. Front Immunol. 2023;14:1283120.","journal-title":"Front Immunol"},{"key":"926_CR49","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1097\/INF.0000000000001916","volume":"37","author":"JB Domachowske","year":"2018","unstructured":"Domachowske JB, Khan AA, Esser MT, Jensen K, Takas T, Villafana T, et al. Safety, tolerability and pharmacokinetics of MEDI8897, an extended half-life single-dose respiratory syncytial virus prefusion F-targeting monoclonal antibody administered as a single dose to healthy preterm infants. Pediatr Infect Dis J. 2018;37:886\u201392.","journal-title":"Pediatr Infect Dis J"},{"key":"926_CR50","unstructured":"Beyfortus SPC. 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/beyfortus-epar-product-information_en.pdf. Accessed 31 Jul 2024."},{"key":"926_CR51","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1056\/NEJMoa1913556","volume":"383","author":"MP Griffin","year":"2020","unstructured":"Griffin MP, Yuan Y, Takas T, Domachowske JB, Madhi SA, Manzoni P, et al. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med. 2020;383:415\u201325.","journal-title":"N Engl J Med"},{"key":"926_CR52","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1056\/NEJMoa2110275","volume":"386","author":"LL Hammitt","year":"2022","unstructured":"Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med. 2022;386:837\u201346.","journal-title":"N Engl J Med"},{"key":"926_CR53","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S2352-4642(22)00321-2","volume":"7","author":"EAF Sim\u00f5es","year":"2023","unstructured":"Sim\u00f5es EAF, Madhi SA, Muller WJ, Atanasova V, Bosheva M, Caba\u00f1as F, et al. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials. Lancet Child Adolesc Health. 2023;7:180\u20139.","journal-title":"Lancet Child Adolesc Health"},{"key":"926_CR54","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1056\/NEJMc2214773","volume":"388","author":"WJ Muller","year":"2023","unstructured":"Muller WJ, Madhi SA, Seoane Nu\u00f1ez B, Baca Cots M, Bosheva M, Dagan R, et al. Nirsevimab for prevention of RSV in term and late-preterm infants. N Engl J Med. 2023;388:1533\u20134.","journal-title":"N Engl J Med"},{"key":"926_CR55","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1093\/jpids\/piad113","volume":"13","author":"R Dagan","year":"2024","unstructured":"Dagan R, Hammitt LL, Seoane Nu\u00f1ez B, Baca Cots M, Bosheva M, Madhi SA, et al. Infants receiving a single dose of nirsevimab to prevent RSV do not have evidence of enhanced disease in their second RSV season. J Pediatric Infect Dis Soc. 2024;13:144\u20137.","journal-title":"J Pediatric Infect Dis Soc"},{"key":"926_CR56","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/s41591-023-02316-5","volume":"29","author":"D Wilkins","year":"2023","unstructured":"Wilkins D, Yuan Y, Chang Y, Aksyuk AA, N\u00fa\u00f1ez BS, W\u00e4hlby-Hamr\u00e9n U, et al. Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants. Nat Med. 2023;29:1172\u20139.","journal-title":"Nat Med"},{"key":"926_CR57","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1056\/NEJMc2112186","volume":"386","author":"J Domachowske","year":"2022","unstructured":"Domachowske J, Madhi SA, Sim\u00f5es EAF, Atanasova V, Caba\u00f1as F, Furuno K, et al. Safety of nirsevimab for RSV in infants with heart or lung disease or prematurity. N Engl J Med. 2022;386:892\u20134.","journal-title":"N Engl J Med"},{"key":"926_CR58","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa2309189","volume":"389","author":"SB Drysdale","year":"2023","unstructured":"Drysdale SB, Cathie K, Flamein F, Knuf M, Collins AM, Hill HC, et al. Nirsevimab for prevention of hospitalizations due to RSV in infants. N Engl J Med. 2023;389:2425\u201335.","journal-title":"N Engl J Med"},{"key":"926_CR59","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3390\/vaccines12060640","volume":"12","author":"M Ricc\u00f2","year":"2024","unstructured":"Ricc\u00f2 M, Cascio A, Corrado S, Bottazzoli M, Marchesi F, Gili R, et al. Impact of nirsevimab immunization on pediatric hospitalization rates: a systematic review and meta-analysis (2024). Vaccines. 2024;12:640.","journal-title":"Vaccines"},{"key":"926_CR60","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3390\/pathogens13060503","volume":"13","author":"VS Mankad","year":"2024","unstructured":"Mankad VS, Leach A, Chang Y, W\u00e4hlby Hamr\u00e9n U, Kiazand A, Kubiak RJ, et al. Comprehensive summary of safety data on mirsevimab in infants and children from all pivotal randomized clinical trials. Pathogens. 2024;13:503.","journal-title":"Pathogens"},{"issue":"Supplement 1","key":"926_CR61","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1182\/blood-2023-189096","volume":"142","author":"JB Domachowske","year":"2023","unstructured":"Domachowske JB, Hamren UW, Basavaraju B, Koen A, Leach A, Makad VS, et al. Safety, tolerability, and pharmacokinetics of nirsevimab for the prevention of RSV disease in immunocompromised children aged \u226424 months: Music, an open label, phase 2 trial. Blood. 2023;142:1173.","journal-title":"Blood"},{"key":"926_CR62","doi-asserted-by":"publisher","first-page":"209","DOI":"10.15585\/mmwr.mm7309a4","volume":"73","author":"HL Moline","year":"2024","unstructured":"Moline HL, Tannis A, Toepfer AP, Williams JV, Boom JA, Englund JA, et al. Early estimate of nirsevimab effectiveness for prevention of respiratory syncytial virus-associated hospitalization among infants entering their first respiratory syncytial virus season - new vaccine surveillance network, October 2023-February 2024. MMWR Morb Mortal Wkly Rep. 2024;73:209\u201314.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"926_CR63","doi-asserted-by":"publisher","first-page":"e170","DOI":"10.1542\/hpeds.2023-007639","volume":"14","author":"E Aragona","year":"2024","unstructured":"Aragona E, Joshi NS, Birnie KL, Lysouvakon P, Basuray RG. Early experiences with nirsevimab: perspectives from newborn hospitalists. Hosp Pediatr. 2024;14:e170\u20132.","journal-title":"Hosp Pediatr"},{"key":"926_CR64","doi-asserted-by":"publisher","first-page":"920","DOI":"10.15585\/mmwr.mm7234a4","volume":"72","author":"JM Jones","year":"2023","unstructured":"Jones JM, Fleming-Dutra KE, Prill MM, Roper LE, Brooks O, S\u00e1nchez PJ, et al. Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: recommendations of the advisory committee on immunization practices - United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72:920\u20135.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"926_CR65","doi-asserted-by":"publisher","first-page":"S282","DOI":"10.1093\/infdis\/jiac216","volume":"226","author":"A Kieffer","year":"2022","unstructured":"Kieffer A, Beuvelet M, Sardesai A, Musci R, Milev S, Roiz J, et al. Expected impact of universal immunization with nirsevimab against RSV-related outcomes and costs among all US infants in their first RSV season: a static model. J Infect Dis. 2022;226:S282\u201392.","journal-title":"J Infect Dis"},{"key":"926_CR66","unstructured":"Payne A. Summary of effectiveness of nirsevimab in infants. 2024. https:\/\/www.cdc.gov\/acip\/downloads\/slides-2024-06-26-28\/04-rsv-mat-peds-payne-508.pdf. Accessed Jul 2024."},{"key":"926_CR67","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.anpedi.2023.09.001","volume":"99","author":"M S\u00e1nchez Luna","year":"2023","unstructured":"S\u00e1nchez Luna M, Fern\u00e1ndez Colomer B, Couce Pico ML. Recommendations of the Spanish Society of Neonatology for the prevention of severe respiratory syncytial virus infections with nirsevimab, for the 2023\u20132024 season. An De Pediatr\u00eda Engl Ed. 2023;99:264\u20135.","journal-title":"An De Pediatr\u00eda Engl Ed"},{"key":"926_CR68","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.anpedi.2023.09.008","volume":"99","author":"A Iofr\u00edo de Arce","year":"2023","unstructured":"Iofr\u00edo de Arce A, \u00c1lvarez Garc\u00eda FJ. Nirsevimab and other strategies for the prevention of RSV infection. An De Pediatr\u00eda Engl Ed. 2023;99:221\u20133.","journal-title":"An De Pediatr\u00eda Engl Ed."},{"key":"926_CR69","first-page":"2300606","volume":"28","author":"F Martin\u00f3n-Torres","year":"2023","unstructured":"Martin\u00f3n-Torres F, Mir\u00e1s-Carballal S, Dur\u00e1n-Parrondo C. Early lessons from the implementation of universal respiratory syncytial virus prophylaxis in infants with long-acting monoclonal antibodies, Galicia, Spain, September and October 2023. Eur Commun Dis Bull. 2023;28:2300606.","journal-title":"Eur Commun Dis Bull"},{"key":"926_CR70","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S1473-3099(24)00215-9","volume":"24","author":"S Ares-G\u00f3mez","year":"2024","unstructured":"Ares-G\u00f3mez S, Mallah N, Santiago-P\u00e9rez MI, Pardo-Seco J, P\u00e9rez-Mart\u00ednez O, Otero-Barr\u00f3s MT, et al. Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study. Lancet Infect Dis. 2024;24:817\u201328.","journal-title":"Lancet Infect Dis"},{"key":"926_CR71","first-page":"2400046","volume":"29","author":"M L\u00f3pez-Lacort","year":"2024","unstructured":"L\u00f3pez-Lacort M, Mu\u00f1oz-Quiles C, Mira-Iglesias A, L\u00f3pez-Labrador FX, Mengual-Chuli\u00e1 B, Fern\u00e1ndez-Garc\u00eda C, et al. Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024. Eur Commun Dis Bull. 2024;29:2400046.","journal-title":"Eur Commun Dis Bull"},{"key":"926_CR72","doi-asserted-by":"publisher","first-page":"5181","DOI":"10.1007\/s00431-024-05779-x","volume":"183","author":"A Perramon-Malavez","year":"2024","unstructured":"Perramon-Malavez A, de Rioja VL, Coma E, Hermosilla E, Fina F, Mart\u00ednez-Marcos M, et al. Introduction of nirsevimab in Catalonia, Spain: description of the incidence of bronchiolitis and respiratory syncytial virus in the 2023\/2024 season. Eur J Pediatr. 2024;183:5181\u20139.","journal-title":"Eur J Pediatr"},{"key":"926_CR73","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.eimc.2024.11.007","volume":"43","author":"E Gregori-Garc\u00eda","year":"2025","unstructured":"Gregori-Garc\u00eda E, Gasc\u00f3-Laborda JC, Lluch-Bacas L, P\u00e9rez-Olaso O, G\u00f3mez-Alfaro I, Bellido-Blasco JB. Impact of the passive immunization campaign with nirsevimab in 2023\u201324 in Castell\u00f3n. Final results.\u00a0Enferm Infecc Microbiol Clin (Engl Ed). 2025;43:215\u201358.","journal-title":"Enfermedades Infecciosas Y Microbiol Clin Engl Ed"},{"key":"926_CR74","doi-asserted-by":"publisher","first-page":"e2024066393","DOI":"10.1542\/peds.2024-066393","volume":"155","author":"M L\u00f3pez-Lacort","year":"2025","unstructured":"L\u00f3pez-Lacort M, Mu\u00f1oz-Quiles C, Mira-Iglesias A, Xavier L\u00f3pez-Labrador F, Garc\u00e9s-S\u00e1nchez M, Escribano-L\u00f3pez B, et al. Nirsevimab effectiveness against severe respiratory syncytial virus infection in the primary care setting. Pediatrics. 2025;155:e2024066393.","journal-title":"Pediatrics"},{"key":"926_CR75","first-page":"2400596","volume":"30","author":"O N\u00fa\u00f1ez","year":"2025","unstructured":"N\u00fa\u00f1ez O, Olmedo C, Moreno-Perez D, Lorusso N, Fern\u00e1ndez Mart\u00ednez S, Pastor Villalba PE, et al. Effectiveness of catch-up and at-birth nirsevimab immunisation against RSV hospital admission in the first year of life: a population-based case-control study, Spain, 2023\/24 season. Eur Commun Dis Bull. 2025;30:2400596.","journal-title":"Eur Commun Dis Bull"},{"key":"926_CR76","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/archdischild-2024-327153","volume":"109","author":"E Coma","year":"2024","unstructured":"Coma E, Martinez-Marcos M, Hermosilla E, Mendioroz J, Re\u00f1\u00e9 A, Fina F, et al. Effectiveness of nirsevimab immunoprophylaxis against respiratory syncytial virus-related outcomes in hospital and primary care settings: a retrospective cohort study in infants in Catalonia (Spain). Arch Dis Child. 2024;109:736\u201341.","journal-title":"Arch Dis Child"},{"key":"926_CR77","doi-asserted-by":"publisher","first-page":"383","DOI":"10.3390\/vaccines12040383","volume":"12","author":"G Ezpeleta","year":"2024","unstructured":"Ezpeleta G, Navascu\u00e9s A, Viguria N, Herranz-Aguirre M, Juan Belloc SE, Gimeno Ballester J, et al. Effectiveness of nirsevimab immunoprophylaxis administered at birth to prevent infant hospitalisation for respiratory syncytial virus infection: a population-based cohort study. Vaccines. 2024;12:383.","journal-title":"Vaccines"},{"key":"926_CR78","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1056\/NEJMoa2314885","volume":"391","author":"Z Assad","year":"2024","unstructured":"Assad Z, Romain AS, Aupiais C, Shum M, Schrimpf C, Lorrot M, et al. Nirsevimab and hospitalization for RSV bronchiolitis. N Engl J Med. 2024;391:144\u201354.","journal-title":"N Engl J Med"},{"key":"926_CR79","doi-asserted-by":"publisher","first-page":"e13311","DOI":"10.1111\/irv.13311","volume":"18","author":"J Paireau","year":"2024","unstructured":"Paireau J, Durand C, Raimbault S, Cazaubon J, Mortamet G, Viriot D, et al. Nirsevimab effectiveness against cases of respiratory syncytial virus bronchiolitis hospitalised in paediatric intensive care units in France, September 2023-January 2024. Influenza Other Respir Viruses. 2024;18:e13311.","journal-title":"Influenza Other Respir Viruses"},{"key":"926_CR80","doi-asserted-by":"publisher","first-page":"549","DOI":"10.3390\/vaccines12050549","volume":"12","author":"A Consolati","year":"2024","unstructured":"Consolati A, Farinelli M, Serravalle P, Rollandin C, Apprato L, Esposito S, et al. Safety and efficacy of nirsevimab in a universal prevention program of respiratory syncytial virus bronchiolitis in newborns and infants in the first year of life in the Valle d\u2019Aosta region, Italy, in the 2023\u20132024 epidemic season. Vaccines. 2024;12:549.","journal-title":"Vaccines"},{"key":"926_CR81","doi-asserted-by":"publisher","first-page":"2400033","DOI":"10.2807\/1560-7917.ES.2024.29.4.2400033","volume":"29","author":"C Ernst","year":"2024","unstructured":"Ernst C, Bejko D, Gaasch L, Hannelas E, Kahn I, Pierron C, et al. Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023\/24 season in Luxembourg. Euro Surveill. 2024;29:2400033.","journal-title":"Euro Surveill"},{"key":"926_CR82","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.anpedi.2024.09.002","volume":"101","author":"M S\u00e1nchez Luna","year":"2024","unstructured":"S\u00e1nchez Luna M, Couce Pico ML, Fern\u00e1ndez CB. Recommendations of the Spanish Society of Neonatology for the prevention of severe respiratory syncytial virus infections with nirsevimab, for the 2024\u20132025 season. An De Pediatr\u00eda Engl Ed. 2024;101:364\u20136.","journal-title":"An De Pediatr\u00eda Engl Ed"},{"key":"926_CR83","unstructured":"Singapore Local Prescribing Information for Arexvy PI version GDS02\/IPI01(SI). 2024. https:\/\/eservice.hsa.gov.sg\/prism\/common\/enquirepublic\/SearchDRBProduct.do?action=load. Accessed 05 May 2025."},{"key":"926_CR84","doi-asserted-by":"publisher","first-page":"251513552098151","DOI":"10.1177\/2515135520981516","volume":"9","author":"KM Eichinger","year":"2021","unstructured":"Eichinger KM, Kosanovich JL, Lipp M, Empey KM, Petrovsky N. Strategies for active and passive pediatric RSV immunization. Ther Adv Vaccines Immunother. 2021;9:2515135520981516.","journal-title":"Ther Adv Vaccines Immunother"},{"key":"926_CR85","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","volume":"388","author":"B Kampmann","year":"2023","unstructured":"Kampmann B, Madhi SA, Munjal I, Sim\u00f5es EAF, Pahud BA, Llapur C, et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med. 2023;388:1451\u201364.","journal-title":"N Engl J Med"},{"key":"926_CR86","unstructured":"AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) for injectable suspension, for intramuscular use. 2024. https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Arexvy\/pdf\/AREXVY.PDF. Accessed 03 Sept 2024."},{"key":"926_CR87","doi-asserted-by":"crossref","unstructured":"Fleming-Dutra KE, Jones JM, Roper LE, Prill MM, Ortega-Sanchez IR, Moulia DL, et al. Use of the Pfizer respiratory syncytial virus vaccine during pregnancy for the prevention of respiratory syncytial virus\u2013associated lower respiratory tract disease in infants: Recommendations of the Advisory Committee on Immunization Practices \u2014 United States, 2023. 2023. https:\/\/www.cdc.gov\/mmwr\/volumes\/72\/wr\/mm7241e1.htm. Accessed 03 Sept 2024.","DOI":"10.15585\/mmwr.mm7241e1"},{"key":"926_CR88","unstructured":"Clinical Guidance for RSV Immunizations and Vaccines. 2024. https:\/\/www.cdc.gov\/rsv\/hcp\/vaccine-clinical-guidance\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/vaccines\/vpd\/rsv\/hcp\/pregnant-people.html. Accessed 03 Sept 2024."},{"key":"926_CR89","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1056\/NEJMoa2305478","volume":"390","author":"I Dieussaert","year":"2024","unstructured":"Dieussaert I, Kim JH, Luik S, Seidl C, Pu W, Stegmann JU, et al. RSV prefusion F protein-based maternal vaccine - preterm birth and other outcomes. N Engl J Med. 2024;390:1009\u201321.","journal-title":"N Engl J Med"},{"key":"926_CR90","doi-asserted-by":"publisher","first-page":"251513552413106","DOI":"10.1177\/25151355241310601","volume":"13","author":"K Kelleher","year":"2025","unstructured":"Kelleher K, Subramaniam N, Drysdale SB. The recent landscape of RSV vaccine research. Ther Adv Vaccines Immunother. 2025;13:25151355241310600.","journal-title":"Ther Adv Vaccines Immunother"},{"key":"926_CR91","doi-asserted-by":"publisher","first-page":"e478","DOI":"10.1093\/infdis\/jiae581","volume":"231","author":"SA Madhi","year":"2025","unstructured":"Madhi SA, Sim\u00f5es EAF, Acevedo A, Novoa Pizarro JM, Shepard JS, Railkar RA, et al. A phase 1b\/2a trial of a half-life extended respiratory syncytial virus neutralizing antibody, clesrovimab, in healthy preterm and full-term infants. J Infect Dis. 2025;231:e478\u201387.","journal-title":"J Infect Dis"}],"container-title":["World Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12519-025-00926-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12519-025-00926-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12519-025-00926-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T05:07:21Z","timestamp":1763528841000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12519-025-00926-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":91,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["926"],"URL":"https:\/\/doi.org\/10.1007\/s12519-025-00926-2","relation":{},"ISSN":["1708-8569","1867-0687"],"issn-type":[{"value":"1708-8569","type":"print"},{"value":"1867-0687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"11 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article was originally published under the subscription model but it is now published under an Open Access license.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"GDYT, LJH, CCK, KPC, LBW, GA, and TKC have no conflict of interest to disclose. CSM received consulting fees from Sanofi, MSD, Roche, and Sandoz. YCF received consulting fees from Sanofi, Pfizer, and Moderna and research grants from NMRC, Wellcome Trust, and Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}